Boston Scientific (BSX) is a publicly traded Healthcare sector company. As of October 1, 2026, BSX trades at $43.69 with a market cap of $63.59B and a P/E ratio of 17.55. BSX moved -0.12% today. Year to date, BSX is -53.91%; over the trailing twelve months it is -55.29%. Its 52-week range spans $42.20 to $109.50. Analyst consensus is strong buy with an average price target of $58.58. Rallies surfaces BSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
US FDA classifies Imager II catheter recall as Class I due to injury risk: The FDA classified Boston Scientific’s Imager II angiographic catheter recall as Class I, the most serious type. The company reported two serious injuries and no deaths and decided to discontinue the product line.
| Metric | Value |
|---|---|
| Price | $43.69 |
| Market Cap | $63.59B |
| P/E Ratio | 17.55 |
| EPS | $2.49 |
| Dividend Yield | 0.00% |
| 52-Week High | $109.50 |
| 52-Week Low | $42.20 |
| Volume | 13.99M |
| Avg Volume | 0 |
| Revenue (TTM) | $21.00B |
| Net Income | $3.67B |
| Gross Margin | 69.93% |
21 analysts cover BSX: 0 strong buy, 18 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $58.58.